|
|
Post by mnkdfann on Oct 29, 2018 17:56:41 GMT -5
Is there a milestone due for MNKD on this event?? IDK for sure, but I would doubt it. It doesn't seem like a 'milestone' event to me. Since the funding raise was only $29 million, any milestone payment would presumably have to amount to chump change anyway. |
|
|
|
Post by kimi on Oct 29, 2018 18:03:57 GMT -5
Aurora Cannabis Inc. (ACB)
|
|
|
|
Post by sayhey24 on Oct 29, 2018 18:04:32 GMT -5
|
|
|
|
Post by buyitonsale on Oct 29, 2018 18:09:48 GMT -5
"Receptor Holdings also plans to introduce its disruptive technologies to the non-prescription cannabinoid markets that are developing in Canada, Europe and elsewhere." OTC = royalty revenue much sooner than with NDA process... we need $ now  |
|
|
|
Post by mnkdfann on Oct 29, 2018 18:10:06 GMT -5
Aurora Cannabis Inc. (ACB) Where do you see Aurora mentioned? |
|
|
|
Post by itellthefuture777 on Oct 29, 2018 18:10:14 GMT -5
I love the pic of Mannkind's device Front and Center on the RLS Technology page:  "Based on a best-in-class inhaled drug delivery platform" Now...Elon Musk..inhaling from it..would be cool..hmm |
|
|
|
Post by harryx1 on Oct 29, 2018 18:14:13 GMT -5
|
|
|
|
Post by mike0475 on Oct 29, 2018 18:21:37 GMT -5
This doesn’t do anything for mnkd at this point.
We need to hear milestone update.
Once we have milestone from RLS we should also have another from
UT, perhaps that gets us to 5-6 dollars
|
|
|
|
Post by thekindaguyiyam on Oct 29, 2018 18:25:04 GMT -5
"Is Marijuana CBD Better Than Hemp CBD? after seeing the link at the bottom to a product line; I read this with a grain of salt. If CBD is CBD, no matter how it’s created, why is there so much conversation and controversy around this non-psychoactive molecule? This is an excellent question because CBD, in its isolated form, isn’t necessary “powerful” all by itself. No single isolate, and highly concentrated, cannabinoid molecule is potent, safe or useful when it enters the body leading a solo mission. The Father of Cannabis Research, Dr. Raphael Mechoulam, was the first to isolate the cannabinoids CBD and THC from the cannabis plant. He discovered an interesting phenomenon called the entourage effect. Very briefly, the entourage effect says that ALL the cannabinoid molecules need each other to work properly, as nature designed/evolved to be. An unprecedented study by Gallily, R., Yekhtin, Z. and Hanuš, L.O. (2015) “Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol,” explains why single CBD isolate molecules are not recommended vs full-spectrum CBD. This Israeli Team discovered that: “The therapeutic synergy observed with plant extracts results in the requirement for a lower amount of active components, with consequent reduced adverse effects.” Since the CBD molecule is the same CBD molecule, it doesn’t matter how or where you get your CBD molecule, except to the legal system with marijuana CBD. What is important about CBD is that you do NOT take CBD in a single or isolated form. The reason for NOT ingesting a single cannabinoid is because of the entourage effect. The best and most efficient CBD Products will have a blend of many many other Cannabinoids extracted from the whole plant, among other ancient wonders. More Cannabinoid diversity will bring a more holistic effect for the results you seek to achieve with hemp CBD." www.biocbdplus.com/marijuana-cbd-vs-hemp-cbd |
|
|
|
Post by sportsrancho on Oct 29, 2018 18:26:03 GMT -5
|
|
|
|
Post by porkini on Oct 29, 2018 18:27:28 GMT -5
This doesn’t do anything for mnkd at this point. We need to hear milestone update. Once we have milestone from RLS we should also have another from UT, perhaps that gets us to 5-6 dollars Do you have a link for that? My convoluted logic... I don't do anything for mnkd at this point, so, I am equal to RLS! NOT!    |
|
|
|
Post by goyocafe on Oct 29, 2018 18:29:58 GMT -5
|
|
|
|
Post by sportsrancho on Oct 29, 2018 18:32:23 GMT -5
☰
Receptor Life Sciences raises $29M, unveils its work on inhaler for medicines based on cannabis
By Clare McGrane on October 29, 2018 at 1:43 pm
Receptor Life Sciences CEO Gregory Wesner. (Lane Powell Photo)
Seattle-based biotech company Receptor Life Sciences announced a $29 million series A funding round Monday as it emerged from stealth mode, unveiling its work on medicines derived from cannabis.
The $29 million is the first time the company has raised funds. Through a spokesperson, it declined to identify its investors.
Arthur Rubinfeld, a longtime executive at Starbucks, is listed as a director of the company in an SEC filing that disclosed the new funding. Rubinfeld left Starbucks, where he was most recently the president of global innovation at the company’s roastery, in 2016. He is also the founder of Airvision, an advisory firm specializing in consumer oriented businesses.
|
|
|
|
Post by sayhey24 on Oct 29, 2018 18:35:22 GMT -5
"The $29 million is the first time the company has raised funds. Through a spokesperson, it declined to identify its investors. Arthur Rubinfeld, a longtime executive at Starbucks, is listed as a director of the company in an SEC filing that disclosed the new funding. Rubinfeld left Starbucks, where he was most recently the president of global innovation at the company’s roastery, in 2016. He is also the founder of Airvision, an advisory firm specializing in consumer oriented businesses."
And let me add - a long time friend of Kevin Johnson, CEO of Starbucks since their days at Microsoft. I see Arthur is not listed on their website. Maybe its better that way for now.
|
|
|
|
Post by mnkdfann on Oct 29, 2018 18:38:08 GMT -5
☰ Receptor Life Sciences raises $29M, unveils its work on inhaler for medicines based on cannabis By Clare McGrane on October 29, 2018 at 1:43 pm Receptor Life Sciences CEO Gregory Wesner. (Lane Powell Photo) Seattle-based biotech company Receptor Life Sciences announced a $29 million series A funding round Monday as it emerged from stealth mode, unveiling its work on medicines derived from cannabis. The $29 million is the first time the company has raised funds. Through a spokesperson, it declined to identify its investors.Arthur Rubinfeld, a longtime executive at Starbucks, is listed as a director of the company in an SEC filing that disclosed the new funding. Rubinfeld left Starbucks, where he was most recently the president of global innovation at the company’s roastery, in 2016. He is also the founder of Airvision, an advisory firm specializing in consumer oriented businesses. Is that a mistake, or does this mean that the previous raise was included in this one? Or are they the same raise, and the value just increased? mnkd.proboards.com/thread/10535/raises-therapies-based-plant-extracts"Secretive biotechnology company Receptor Life Sciences has raised a funding round totaling just over $7.5 million, according to a filing with the Securities and Exchange Commission." |
|
